Naltrexone extended-release plus bupropion extended-release for treatment of obesity.
作者信息
Yanovski Susan Z, Yanovski Jack A
机构信息
Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
Section on Growth and Obesity, Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
出版信息
JAMA. 2015;313(12):1213-4. doi: 10.1001/jama.2015.1617.
Abstract
摘要
相似文献
1
Naltrexone extended-release plus bupropion extended-release for treatment of obesity.
JAMA. 2015;313(12):1213-4. doi: 10.1001/jama.2015.1617.
2
Contrave--a combination of bupropion and naltrexone for weight loss.
Med Lett Drugs Ther. 2014 Nov 10;56(1455):112-4.
3
Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
Expert Rev Clin Pharmacol. 2016;9(1):27-34. doi: 10.1586/17512433.2016.1100072. Epub 2015 Oct 29.
4
ACS chemical neuroscience molecule spotlight on contrave.
ACS Chem Neurosci. 2011 Sep 21;2(9):484-6. doi: 10.1021/cn200076y.
5
[Mysimba, an American appetite suppressant and the logic of the single European market].
Rev Med Suisse. 2015 Apr 15;11(470):890-1.
6
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Expert Opin Drug Saf. 2014 Jun;13(6):831-41. doi: 10.1517/14740338.2014.909405. Epub 2014 Apr 28.
7
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Expert Opin Drug Saf. 2017 Jan;16(1):27-39. doi: 10.1080/14740338.2017.1247807. Epub 2016 Oct 24.
8
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.
Clin Obes. 2016 Oct;6(5):305-12. doi: 10.1111/cob.12157. Epub 2016 Aug 1.
9
Naltrexone ER/Bupropion ER: A Review in Obesity Management.
Drugs. 2015 Jul;75(11):1269-80. doi: 10.1007/s40265-015-0427-5.
10
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
Future Cardiol. 2016 Mar;12(2):129-38. doi: 10.2217/fca.15.79. Epub 2015 Dec 18.
引用本文的文献
1
Paradigm shift in obesity treatment: an extensive review of current pipeline agents.
Turk J Med Sci. 2025 Jan 15;55(1):1-16. doi: 10.55730/1300-0144.5938. eCollection 2025.
2
Managing obesity in adults with type 1 diabetes.
Diabetes Res Clin Pract. 2025 Feb;220:111983. doi: 10.1016/j.diabres.2024.111983. Epub 2024 Dec 31.
3
Old and new anti-obesity drugs.
J Diabetes Metab Disord. 2024 Dec 19;24(1):16. doi: 10.1007/s40200-024-01512-5. eCollection 2025 Jun.
4
Weight Loss Pharmacotherapy: Current and Future Therapies.
Gastrointest Endosc Clin N Am. 2024 Oct;34(4):591-608. doi: 10.1016/j.giec.2024.06.006.
5
Obesity medications: A narrative review of current and emerging agents.
Osteoarthr Cartil Open. 2024 Apr 25;6(2):100472. doi: 10.1016/j.ocarto.2024.100472. eCollection 2024 Jun.
6
The relation between excess adiposity and breast cancer in women: Clinical implications and management.
Crit Rev Oncol Hematol. 2024 Jan;193:104213. doi: 10.1016/j.critrevonc.2023.104213. Epub 2023 Nov 24.
7
Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.
Obesity (Silver Spring). 2023 Nov;31(11):2762-2773. doi: 10.1002/oby.23898. Epub 2023 Sep 26.
8
Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial.
Psychol Med. 2023 Dec;53(16):7775-7784. doi: 10.1017/S0033291723001800. Epub 2023 Jun 27.
9
Cognitive-behavioral therapy for binge-eating disorder for non-responders to initial acute treatments: Randomized controlled trial.
Int J Eat Disord. 2023 Aug;56(8):1544-1553. doi: 10.1002/eat.23975. Epub 2023 May 5.
10
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial.
Am J Psychiatry. 2022 Dec 1;179(12):927-937. doi: 10.1176/appi.ajp.20220267. Epub 2022 Oct 26.
本文引用的文献
1
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2985-3023. doi: 10.1016/j.jacc.2013.11.004. Epub 2013 Nov 12.
2
Long-term drug treatment for obesity: a systematic and clinical review.
JAMA. 2014 Jan 1;311(1):74-86. doi: 10.1001/jama.2013.281361.
3
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Diabetes Care. 2013 Dec;36(12):4022-9. doi: 10.2337/dc13-0234. Epub 2013 Oct 21.
4
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Obesity (Silver Spring). 2013 May;21(5):935-43. doi: 10.1002/oby.20309.
5
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29.
6
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Obesity (Silver Spring). 2011 Jan;19(1):110-20. doi: 10.1038/oby.2010.147. Epub 2010 Jun 17.
7
Meta-analysis: pharmacologic treatment of obesity.
Ann Intern Med. 2005 Apr 5;142(7):532-46. doi: 10.7326/0003-4819-142-7-200504050-00012.
Zotero 插件